LA

Leila Alland

Radiopharm Theranostics Limited | Non-Executive Director
Dr. Alland is a biotech advisor working with entrepreneurs and investors to advance diagnostic and therapeutic products for oncology and rare diseases. Dr. Alland also serves on the board of directors of Abeona Therapeutics (NASDAQ: ABEO), a cell and gene therapy company. Previously, Dr. Alland served as CMO of PMV Pharma (NASDAQ, PMVP),an oncology company, and prior to that, as CMO of Affimed (NASDAQ: AFMD), an immuno-oncology company, and as CMO of Tarveda Therapeutics, a targeted drug conjugate company. Her career includes leadership roles at AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough, where she contributed to the development and approvals of Tagrisso, Opdivo, Tasigna, and Caelyx. As Head of Oncology Early Clinical Development at AstraZeneca, she oversaw the company's early oncology portfolio. She completed training in Pediatrics at the Children's Hospital of Philadelphia, and Hematology/Oncology at MemorialSloan-Kettering, and served on the faculty of Albert Einstein College of Medicine. She is Member of risk committee.

Company and Role

Company
Title
Tenure
Since
RAD
Radiopharm Theranostics Limited
  • Non-Executive Director
2yrs, 8mthJun 2022

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
RAD
Radiopharm Theranostics Limited
16/12/241,071,740N/A10,400,002N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
RAD
Radiopharm Theranostics Limited
16/12/24
Issued
8,000,000$0.027$216,000Issue of options
RAD
Radiopharm Theranostics Limited
13/09/24
Issued
500,000$0.030$15,000Placement
RAD
Radiopharm Theranostics Limited
13/09/24
Issued
1,000,000$0.040$40,000Placement
RAD
Radiopharm Theranostics Limited
08/12/23
Issued
71,740$0.070$5,021Rights issue
RAD
Radiopharm Theranostics Limited
05/12/22
Issued
1,900,002$0.115$218,500Issue of options